Harvard, MIT scientists figure out how to control stem cells; RNAi therapy regulates amyloid;

Cancer

> Mersana Therapeutics achieved its second preclinical milestone in its collaboration with Endo Pharmaceuticals for its next-generation Fleximer antibody-drug conjugates. Release

Genetic diseases

> Antibody developer arGEN-X has met two important success milestones in its SIMPLE Antibody research and product development collaboration with Shire for ($SHPG) rare genetic diseases. Release

> In a nonhuman primate study, an RNAi therapy developed by Arcturus Therapeutics decreased transthyretin-mediated amyloidosis by 75%. Release

Stem Cells

> Scientists at Harvard and MIT have engineered cells that can be better controlled after they're transplanted into a host. More